Chemical Compound
Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, (5a,6ss)-; (5a,6ss)-17-(Cyclopropylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-(Cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6ss-ol; 6ss-Hydroxynaltrexone; 6ss-Naltrexol; ss-Naltrexol
CAS Registry Number
49625-89-0
Primary record
Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, (5a,6ss)-; (5a,6ss)-17-(Cyclopropylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-(Cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6ss-ol; 6ss-Hydroxynaltrexone; 6ss-Naltrexol; ss-Naltrexol
- 库存
- 3,674 克
- 纯度
- 99.1 %
- CAS
- 49625-89-0
化合物标识与属性
- CAS
- 49625-89-0
- PubChem CID
- 5486554
- SMILES
- C1C[C@]2([C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@@H]1O)OC5=C(C=C4)O)O
- Canonical SMILES
- Oc1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
名称与同义词
- 6beta-Naltrexol
- beta-Naltrexol
- 6alpha-Naltrexol
- 6-beta-Naltrexol
- naltrexol
- 6|A-Naltrexol
- alpha-Naltrexol
- 6b-Naltrexol
- 6-alpha-naltrexol
- 6beta-Hydroxynaltrexone
- 6alpha-Hydroxynaltrexone
- 6-Naltrexol
- |A-Naltrexol
- 6 beta-naltrexol
- 6,beta-naltrexol
- 6 alpha-naltrexol
- Naltrexone-6-beta-ol
- AIKO-150
- 6beta-Naltrexol-d4
- NTXOL
- 6 Beta-hydroxynaltrexone
- 49625-89-0
- 6-Beta-naltrexol hcl
- .BETA.-NALTREXOL
- 6 alpha-hydroxynaltrexone
- 6|A-Hydroxynaltrexone
- 6-|A-Naltrexol HCl
- 6?-Hydroxy Naltrexone
- Naltrexone impurity 31
- 6.BETA.-NALTREXOL
- 6?-NALTREXOL
- RefChem:544403
- D00HBR
- D0E2BB
- 6-BETA-NALTREXOLHCL
- UNII-J0W963M37T
- DTXSID80197942
- CHEMBL140278
- J0W963M37T
- 6.BETA.-HYDROXYNALTREXONE
- SCHEMBL679700
- JLVNEHKORQFVQJ-PYIJOLGTSA-N
- CHEMBL558140
- orb2567150
- SCHEMBL29379302
- DTXCID40120433
- CHEBI:192658
- EN 2260
- ZINC6092289
- ARD159640
- BDBM50001709
- C20-H25-N-O4
- 6 beta-hydroxynaltrexone, hydrochloride
- 6-beta-Naltrexol, 1mg/ml in Methanol
- CID5486554
- CS-T-57082
- CID:5486554
- 6b-Naltrexol (1.0 mg/mL in Methanol)
- NCGC00165851-01
- DA-49953
- SID:134223741
- HY-108229
- J291.598G
- CS-0027591
- NS00003924
- N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynorisomorphine
- G87745
- (4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
- 20410-98-4
- C010410
- 17-(Cyclopropylmethyl)-4,5-epoxymorphinan-3,6beta,14-triol
- Q19598102
- 17-(Cyclopropylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol
- Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, (5.alpha.,6.beta.)-
- Morphinan-3,6alpha,14-triol, 17-(cyclopropylmethyl)-4,5alpha-epoxy-
- Opioid neutral antagonists (iv, pain), Aiko Biotechnology
- 17-(cyclopropylmethyl)-4,5-epoxymorphinan-3,6 beta,14-triol
- 17-(Cyclopropylmethyl)-5alpha-4,5-epoxymorphinan-3,6beta,14-triol
- 17-Cyclopropylmethyl-4,5alpha-epoxy-3,6beta,14-trihydroxymorphinan
- 17-Cyclopropylmethyl-4,5alpha-epoxymorphinan-3,6beta,14beta-triol
- 4,5alpha-Epoxy-17-cyclopropylmethylmorphinan-3,6beta,14beta-triol
- Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, (5alpha,6beta)-
- 17-(Cyclopropylmethyl)-4,5-epoxy-(5|A,6|A)-morphinan-3,6,14-triol
- (1S,5R,13R,14R,17S)-4-(cyclopropylmethyl)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18)-triene-10,14,17-triol
- (4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-1,2,3,4,5,6,7,7a-octahydro-4aH-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
- (4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzouro[3,2-e]isoquinoline-4a,7,9-triol
- 100678-48-6
- 1279034-32-0
- 17-(Cyclopropylmethyl)-4,5-epoxy-(5?,6?)-morphinan-3,6,14-triol; 6?-Hydroxynaltrexone; ?-Naltrexol;
- 4-cyclopropylmethyl-(13R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18)-triene-10,14,17-triol
- 6beta-Naltrexol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
- Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, (5a,6ss)-; (5a,6ss)-17-(Cyclopropylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-(Cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6ss-ol; 6ss-Hydroxynaltrexone; 6ss-Naltrexol; ss-Naltrexol